LUMINEX CORP

Form 8-K

January 07, 2019

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 7, 2019 (January 7, 2019)

LUMINEX CORPORATION

(Exact name of registrant as specified in its charter)

DELAWARE 000-30109 74-2747608

(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

12212 TECHNOLOGY BLVD., AUSTIN, TEXAS 78727

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (512) 219-8020

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this

chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an

emerging

growth

company,

indicate by

check mark if

the registrant

has elected

not to use the

extended

transition

period for

complying

with any new

or revised

financial

accounting

standards

provided

pursuant to

Section 13(a)

of the

Exchange

Act.

o

Item 2.02. Results of Operations and Financial Condition.

On January 7, 2019, Luminex Corporation ("the Company") issued a press release announcing preliminary revenue for the fourth quarter and full year 2018. A copy of the press release is furnished herewith as Exhibit 99.1

Item 7.01. Regulation FD Disclosure.

On January 9, 2019, the Company is giving a presentation ("Investor Presentation") to investors discussing, among other topics, an overview of the Company's business and growth strategy. The presentation will be at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA and will begin at 5:30 p.m. Pacific time (8:30 p.m. Eastern time). A copy of the Investor Presentation, which is available at www.luminexcorp.com, is being furnished as Exhibit 99.2 to this Form 8-K and is incorporated herein by reference.

The information in Item 2.02 and 7.01 of this Current Report on Form 8-K, including the Press Release attached as Exhibit 99.1 and Investor Presentation attached as Exhibit 99.2, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liabilities under that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 Press Release issued by Luminex Corporation dated January 7, 2019.

99.2 Investor Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 7, 2019 LUMINEX CORPORATION

By: /s/ Harriss T. Currie Name: Harriss T. Currie

Title: Chief Financial Officer, Senior Vice President of Finance